News
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
The analyst further reasoned that the high ocular toxicity rates, including keratopathy and visual acuity changes, are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback